公开(公告)号：US11242395B2

公开(公告)日：2022-02-08

申请号：US16108018

申请日：2018-08-21

Applicant: Adagene Inc.

Inventor： Peter Peizhi Luo ,  Fangyong Du ,  Yan Li ,  Guizhong Liu ,  Jun Chen ,  Xiaohong She ,  Peter Cheung

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/00 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

公开(公告)号：US11859003B2

公开(公告)日：2024-01-02

申请号：US16640684

申请日：2018-08-21

Applicant: Adagene Inc.

Inventor： Peter Peizhi Luo ,  Fangyong Du ,  Guizhong Liu ,  Yan Li ,  Jun Chen ,  Xiaohong She ,  Peter Cheung

IPC: A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  A61K45/06

CPC classification number: C07K16/2878 ,  A61K39/001102 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2818 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.

公开(公告)号：US20190055314A1

公开(公告)日：2019-02-21

申请号：US16108018

申请日：2018-08-21

Applicant: Adagene Inc.

Inventor： Peter Peizhi Luo ,  Fangyong Du ,  Yan Li ,  Guizhong Liu ,  Jun Chen ,  Xiaohong She ,  Peter Cheung

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  A61P35/00

Abstract: The present disclosure provides antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.